FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2240972300> ?p ?o ?g. }

• W2240972300 endingPage "7572" @default.
• W2240972300 startingPage "7572" @default.
• W2240972300 abstract "7572 Background Patients (pts) with metastatic melanoma (MM) have very few therapy options. Based on anecdotal reports of responses to Paclitaxel and Carboplatin (PC), several MM pts were treated with PC in our institution. Here we review our results with PC in a clinical practice setting. Methods Medical records were used to identify MM pts who had got PC, and data abstracted about pt characteristics and outcomes. Response determinations using clinical criteria were noted, and verified according to RECIST criteria, where possible. Results 17 pts (12 men and 5 women) started received weekly carboplatin (AUC=2) and Paclitaxel (100 mg/m2) between 5/2003 and 9/2004. Response evaluations were performed every 3 weeks. 1 pt was lost to follow up after 9 weeks of therapy. Pts were heavily pre-treated; with a mean of 1.8 (range 1–4) prior systemic therapies per pt. Mean duration of therapy was 8 weeks (range 3–21 w). 7 pts progressed (PROG) at the first evaluation, while a subset of pts appeared to have clear clinical benefit. 2 (12%) pts had a partial responses (PR) (including regression of liver metastases and ascites in 1 pt) and continue on therapy after a mean of 7.5 weeks of therapy. 9 (52%) pts had stabilization of disease (SD). In the SD group, the mean time to progression was 12 weeks, with 2 still on PC. Toxicity was tolerable, with only 1 pt needing to stop PC because of side effects to carboplatin. The median number of prior therapies was 2 in those with SD/PR and 2.5 in the PROG group. 4 pts continue on PC, and 3 are receiving other therapies after progressing on PC. Conclusion The main limitation of our study is its retrospective nature, with the presumed clinical bias in selection of pts. Yet, our clinical experience in MM pts appears to suggest that, when used in the salvage setting, weekly PC results in clear clinical benefit in a subset of pts. The degree of activity noted in our experience in this population is higher than may be predicted by previous prospective clinical trials using these drugs in relatively chemotherapy naïve pts (Hodi, et al, Am J Clin Oncol 25; (3) 283–6, 2002 and Zimpfer-Rechner, et al., Melanoma Res 13 (5),531–6, 2003). Further evaluation of weekly PC, alone or as a ‘backbone’ for other agents, should be considered. No significant financial relationships to disclose." @default.
• W2240972300 created "2016-06-24" @default.
• W2240972300 creator A5005336837 @default.
• W2240972300 creator A5032917850 @default.
• W2240972300 creator A5035807701 @default.
• W2240972300 creator A5043185114 @default.
• W2240972300 creator A5045289637 @default.
• W2240972300 creator A5072430869 @default.
• W2240972300 date "2005-06-01" @default.
• W2240972300 modified "2023-10-16" @default.
• W2240972300 title "Weekly paclitaxel and carboplatin may be an option for salvage chemotherapy in stage IV melanoma patients" @default.
• W2240972300 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.7572" @default.
• W2240972300 hasPublicationYear "2005" @default.
• W2240972300 type Work @default.
• W2240972300 sameAs 2240972300 @default.
• W2240972300 citedByCount "0" @default.
• W2240972300 crossrefType "journal-article" @default.
• W2240972300 hasAuthorship W2240972300A5005336837 @default.
• W2240972300 hasAuthorship W2240972300A5032917850 @default.
• W2240972300 hasAuthorship W2240972300A5035807701 @default.
• W2240972300 hasAuthorship W2240972300A5043185114 @default.
• W2240972300 hasAuthorship W2240972300A5045289637 @default.
• W2240972300 hasAuthorship W2240972300A5072430869 @default.
• W2240972300 hasConcept C126322002 @default.
• W2240972300 hasConcept C141071460 @default.
• W2240972300 hasConcept C143998085 @default.
• W2240972300 hasConcept C146357865 @default.
• W2240972300 hasConcept C151730666 @default.
• W2240972300 hasConcept C2776694085 @default.
• W2240972300 hasConcept C2777292972 @default.
• W2240972300 hasConcept C2778239845 @default.
• W2240972300 hasConcept C2778822529 @default.
• W2240972300 hasConcept C2779984678 @default.
• W2240972300 hasConcept C2780496750 @default.
• W2240972300 hasConcept C2780775027 @default.
• W2240972300 hasConcept C2781451048 @default.
• W2240972300 hasConcept C71924100 @default.
• W2240972300 hasConcept C86803240 @default.
• W2240972300 hasConceptScore W2240972300C126322002 @default.
• W2240972300 hasConceptScore W2240972300C141071460 @default.
• W2240972300 hasConceptScore W2240972300C143998085 @default.
• W2240972300 hasConceptScore W2240972300C146357865 @default.
• W2240972300 hasConceptScore W2240972300C151730666 @default.
• W2240972300 hasConceptScore W2240972300C2776694085 @default.
• W2240972300 hasConceptScore W2240972300C2777292972 @default.
• W2240972300 hasConceptScore W2240972300C2778239845 @default.
• W2240972300 hasConceptScore W2240972300C2778822529 @default.
• W2240972300 hasConceptScore W2240972300C2779984678 @default.
• W2240972300 hasConceptScore W2240972300C2780496750 @default.
• W2240972300 hasConceptScore W2240972300C2780775027 @default.
• W2240972300 hasConceptScore W2240972300C2781451048 @default.
• W2240972300 hasConceptScore W2240972300C71924100 @default.
• W2240972300 hasConceptScore W2240972300C86803240 @default.
• W2240972300 hasIssue "16_suppl" @default.
• W2240972300 hasLocation W22409723001 @default.
• W2240972300 hasOpenAccess W2240972300 @default.
• W2240972300 hasPrimaryLocation W22409723001 @default.
• W2240972300 hasRelatedWork W2053778437 @default.
• W2240972300 hasRelatedWork W2072767112 @default.
• W2240972300 hasRelatedWork W2075452221 @default.
• W2240972300 hasRelatedWork W2105623825 @default.
• W2240972300 hasRelatedWork W2131564505 @default.
• W2240972300 hasRelatedWork W2261491225 @default.
• W2240972300 hasRelatedWork W2569260518 @default.
• W2240972300 hasRelatedWork W2763599771 @default.
• W2240972300 hasRelatedWork W4296767593 @default.
• W2240972300 hasRelatedWork W2517737960 @default.
• W2240972300 hasVolume "23" @default.
• W2240972300 isParatext "false" @default.
• W2240972300 isRetracted "false" @default.
• W2240972300 magId "2240972300" @default.
• W2240972300 workType "article" @default.